InGeneron, Inc.
Houston, TX
Program data pending ClinicalTrials.gov matching
57.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (4)
○ EMA GMP
○ MHRA GMP
Quick Facts: InGeneron, Inc.
- Signal Score
- 57.5/100
- Quality Compliance
- Assessment pending
- Headquarters
- Houston, TX
- Modalities
- Autologous Cell Therapy (ADRC/point-of-care), Adipose-Derived Regenerative Cells (ADRC), Medical Device (cell separation/processing platform)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About InGeneron, Inc.
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAutologous Cell Therapy (ADRC/point-of-care), Adipose-Derived Regenerative Cells (ADRC), Medical Device (cell separation/processing platform)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
55.0
Manufacturing site information being gathered
Modalities: Autologous Cell Therapy (ADRC/point-of-care), Adipose-Derived Regenerative Cells (ADRC), Medical Device (cell separation/processing platform)
Capacity assessment: 55.0/100
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press4 articles
Manufacturing site information being gathered
Modalities: Autologous Cell Therapy (ADRC/point-of-care), Adipose-Derived Regenerative Cells (ADRC), Medical Device (cell separation/processing platform)
Capacity assessment: 55.0/100
Recent News 4 articles
Sanford Health pioneers use of body’s own stem cells - Sanford Health News
Management of partial-thickness rotator cuff tears with autologous adipose-derived regenerative cells is safe and more effective than injection of corticosteroid | Scientific Reports - Nature
METRO launches self-driving shuttle, Data Gumbo hires new exec, and more Houston innovation news - InnovationMap
Houston sees massive growth in startup venture capital investments from Q1 to Q2 - InnovationMap
Frequently Asked Questions About InGeneron, Inc.
What is InGeneron, Inc.'s CDMO Signal Score?
InGeneron, Inc. has a Signal Score of 58/100, based on quality, operations, financial stability, and capacity data.
Evaluating InGeneron, Inc. for a manufacturing program?
Use the free AI matchmaker to compare InGeneron, Inc. against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: